AKT1 and neoplasm: To measure the effects of BKM120 in an in vivo setting, PtenG129E/+;Akt-FRET mice were allowed to develop primary mammary carcinomas for up to 359 ± 25 days and engrafted with a mammary imaging window (MIW) over the primary tumor (Fig. 5A).